News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The stench of illegal, undisclosed-compensated-promotion permeates CNER.
Section 17(b) of the Securities Act of 1933 ("the Securities Act") mandates that if a person is paid by an issuer to promote a security, the person must disclose the nature, source and amount of such compensation.
With regards to the CNER undisclosed, compensated promotion:
Section 17(b) of the Securities Act of 1933 ("the Securities Act") mandates that if a person is paid by an issuer to promote a security, the person must disclose the nature, source and amount of such compensation.
The stench of illegal promotion permeates CNER.
GM!
I see the undisclosed, compensated pump crew…
has infected CNER.
Nothing good ever comes from these paid CNER promotions.
Buyer beware.
CNER Significant press today. Looking for a strong close!
The Hawaii State Department of Health, in their Published Hawaii Diabetes Plan 2030, states, "Diabetes costs Hawai'i $1.1 billion in direct healthcare expenditures and is currently the 8th leading cause of death in the state. Nearly one in every four healthcare dollars goes toward the care of people with diabetes. On average, people with diabetes incur more than twice the medical costs of people without diabetes.
$CNER - Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029 https://marketwirenews.com/news-releases/increase-prevalence-of-diabetic-patients-driving-mar-5108891115016704.html
Adding here, great opportunity!
CNER .025 x .0299 Open of .03245 !!
Thanks! Great news Expansion into Hawaii, they keep growing nice $CNER
NEWS: China New Energy Group Company/ Thrive Precision Health Announces Agreement To Acquire Two Diabetes Clinics in Hawaii
-PR Newswire
Fri, November 17, 2023 at 8:00 AM EST·5 min read
In this article: CNER +0.0646%
Thrive Focus: Personalized Medicine - Institutionalizing Diabetes Care for Better Patient Outcomes
SPOKANE, Wash., Nov. 17, 2023 /PRNewswire/ -- Thrive Precision Health ("THRV") (formerly Thrive Global Biosafety and China New Energy Group Company (with subsidiary Thrive Testing and Biosafety Inc., "CNER" or "Company") (OTC-Pink-Alternative Reporting Pink: CNER) is pleased to announce it has entered into an agreement to acquire all of the assets of two diabetes clinics in Hawaii with the plan to expand to 20 clinics.
"Diabetes is a big problem among the population in Hawaii, and our focus will be to reduce the pain, struggle, and cost of the diabetes epidemic and its co-morbidities.", stated Guy Zajonc, CEO and Chairman of Thrive Precision Health." "Acquisition of Heal Diabetes, Inc. will give us the footprint to build Thrive Clinics across Hawaii. The management team is highly skilled in delivering the newest forms of diabetes treatment."
Heal Diabetes has 2 locations operating and has billed $1.2M in diabetic care service year to date in 2023 and is seeing consistent month-over-month growth. Over 350 patients have been treated in 2023 at the Honolulu HI and Waipahu HI clinics. We plan to open two more clinics in early 2024. The first one in Waipahu to accommodate a waitlist of 200 patients. And the second new clinic in Waianae, HI, to serve over 4,500 diabetic patients through network referrals.
"The Thrive Precision Health vision to apply advanced technology to diabetes care and individualizing each patient's care is the next evolutionary step in digital health. When advanced technology focuses on a specific problem as large as diabetes, we believe patient outcomes will be better by avoiding expensive treatments like amputation, dialysis, and chronic pain," stated Charles Elliott, President of Heal Diabetes. "Our experience in delivering care on the front lines combined with Thrive's technology is something my team wants to be part of."
THRV will start with the two operational clinics and work to fund the startup of the next two clinics in Q1 2024. Based on demographics and demand, THRV expects to serve the diabetic community across Hawaii with 20 clinics. Each clinic will have a standardized footprint with digital workflows to guide patients and clinicians on optimal care procedures.
The Hawaii State Department of Health, in their Published Hawaii Diabetes Plan 2030, states, "Diabetes costs Hawai'i $1.1 billion in direct healthcare expenditures and is currently the 8th leading cause of death in the state. Nearly one in every four healthcare dollars goes toward the care of people with diabetes. On average, people with diabetes incur more than twice the medical costs of people without diabetes.
For more details on the report, click the link below:
https://hhsp.hawaii.gov/assets/pdf/HHSP_Diabetes_Plan_WEB.pdf
The acquisition is an asset purchase transaction is an all-stock acquisition and will close once Thrive Precision Health Hawaii Inc. (a wholly owned subsidiary of Thrive Precision Health Inc.) completes its mandatory credentialing in Hawaii, estimated to be 90-120 days. During this hold period, THRV will advance funds to Heal Diabetes to expand their operations and add the two new locations.
Thrive Precision Health Inc., has made an application to FINRA for a name and symbol change as it appears on the OTC Markets web site (currently reported as China New Energy Group Company, OTC:CNER). Corporately the name has been changed in the State of Delaware and legally operates as Thrive Precision Health Inc.
About Thrive Precision Health Inc.
Thrive Precision Health, Inc. ("Thrive") is building a global diabetes care powerhouse. We are starting or acquiring established healthcare clinics specializing in diabetes care and bringing in three cutting-edge technologies to make them even better. Our goal is to provide top-notch care to patients worldwide with a seamless digital experience. Imagine if your healthcare was as unique as you are. We use AI and quantum biosensors to analyze data down to the molecular level, tailoring treatments and recommendations specifically for you. This means no more one-size-fits-all solutions. Your health decisions will be based on your personal data, ensuring you receive the most effective and personalized care possible. Leveraging this groundbreaking technology and clinical services will include Wound Care, Neuropathy Care, PIR diabetes care through advanced infusion methods, and conventional and complementary treatment to improve patient outcomes. All services will be performed within a biosafety-secured facility using our biodefense technology to protect our suspectable patients and staff from bacterial and viral infections.
Follow:
Web: www.thriveprecision.health
Linkedin: https://www.linkedin.com/company/thrive-precision-health1/
Twitter: https://twitter.com/PrecisionT67828
Facebook: https://www.facebook.com/profile.php?id=100092725167875&mibextid=LQQJ4d
Important Notice Regarding Forward-Looking Statements
This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of present or historical fact included in this press release, regarding the Company's future financial performance, as well as the Company's strategy, future operations, revenue guidance, projected costs, prospects, plans, and objectives of management are forward-looking statements. When used in this press release, the words "could," "should," "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," the negative of such terms and other similar expressions are intended to identify forward-looking statements. However, not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events. They are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release. Nothing in this release is intended to be an offer of sale or purchase of any securities nor a solicitation of any offer for the sale or purchase of any securities.
China New Energy Group Company/Thrive Precision Health Contact:
Guy Zajonc
CEO
guy@thrivebiosafety.com
U.S. +1 (509) 230-1177
Logo - https://mma.prnewswire.com/media/2256819/4410995/Thrive_Precision_Health_Logo.jpg
Cision
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/china-new-energy-group-companythrive-precision-health-announces-agreement-to-acquire-two-diabetes-clinics-in-hawaii-301991447.html
SOURCE Thrive Precision Health
$CNER huge premarket news: CHINA NEW ENERGY GROUP COMPANY/THRIVE PRECISION HEALTH ANNOUNCES AGREEMENT TO ACQUIRE TWO DIABETES CLINICS IN HAWAII https://finance.yahoo.com/news/china-energy-group-company-thrive-130000370.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$CNER's global vision: 32 clinics in Arizona, 20 in Hawaii. Imagine the impact on diabetes care! 🏥💙 #CNERGlobalImpact #DiabetesCare
🌍 $CNER's global vision: 32 clinics in Arizona, 20 in Hawaii. Imagine the impact on diabetes care! 🏥💙 #CNERGlobalImpact #DiabetesCare
— Thrive Precision Health (@PrecisionT67828) November 13, 2023
Good morning $CNER
Nice! CNER potential Short Squeeze about to happen because of an increase in short volume over the past twenty days with very little cover volume!
CNER some volume coming in! Thin to .035's
$CNER .031's green here, super thin!
The insulin market, valued at $21.11 billion in 2022, signifies a substantial financial domain within the broader diabetes care landscape. Predictions hint at its growth to $25 billion by 2030, with North America playing a prominent role, commanding a considerable 38.91% market revenue share in 2022.
Time to buy!
$CNER 🔥 Don't Miss out this week!
https://newsdirect.com/news/thrive-precision-health-inc-otc-cner-taking-steps-to-serve-diabetic-health-sector-929683000
NEWS: Thrive Precision Health, Inc. (OTC:CNER) Taking Steps To Serve Diabetic Health Sector
Thu, November 16, 2023 at 10:00 AM EST
In this article: CNER
Naples, FL --News Direct-- China New Energy Group Co
In the world of healthcare investments, the diabetes care market emerges as a compelling arena ripe with opportunities. Several important factors that may attract some investors are driving the sector's growth.
At the heart of this surge is the continual development of efficient insulin delivery devices. Technological advancements in healthcare are steering manufacturers to innovate in this crucial area. Projections indicate a substantial uptick in the global diabetes care devices market, from $28,942.1 million in 2022 to an anticipated $42,119.3 million by 2028, reflecting a noteworthy compound annual growth rate (CAGR) of 6.4%.
The World Health Organization's recognition of diabetes as a significant global health challenge underscores the urgency for solutions. With over 420 million people affected worldwide, the market demands innovative approaches to address this widespread concern.
The insulin market, valued at $21.11 billion in 2022, signifies a substantial financial domain within the broader diabetes care landscape. Predictions hint at its growth to $25 billion by 2030, with North America playing a prominent role, commanding a considerable 38.91% market revenue share in 2022.
On a domestic scale, the United States presents a vivid picture of the diabetes epidemic. A staggering 37.3 million Americans are diagnosed with diabetes, while an additional 96 million grapple with pre-diabetes. This prevalence is particularly pronounced in the aging population, where 48.8% of those aged 65 or older face the challenges of this health condition.
Looking forward, Global Market Insights anticipates a robust compound annual growth rate of 10% for the diabetes care device market. This projection positions the market to evolve into an $88 billion industry by 2030, offering investors a compelling narrative for potential opportunities in this evolving healthcare landscape.
Among the growing landscape of the diabetes care market, one potential hidden gem poised for prominence is Thrive Precision Health, Inc. (OTC: CNER).
Thrive Precision Health Inc. is carving its niche as a global diabetes care powerhouse. Trading under the symbol CNER, the company is revitalizing established healthcare clinics specializing in diabetes care. Their unique approach integrates cutting-edge technologies, aiming to create a seamless digital experience for patients worldwide, offering personalized healthcare through the application of AI and quantum biosensors.
The company marked a significant milestone on October 5, 2023, by completing a name change to Thrive Precision Health, Inc. This strategic move accompanied the establishment of two wholly-owned subsidiaries, Thrive Testing and Biosafety Inc. and Thrive Precision Health (USA), Inc., signaling a commitment to precision health and a broader global vision.
Thrive Precision Health's expansion strategy takes center stage with a recent press release announcing a binding letter of intent to acquire two diabetes clinics in Arizona. The pending acquisition of True Diabetes Neuropathy and Wounds Solutions AZ, LLC, marks the initiation of their strategy to infuse advanced technology into diabetes care.
The company is diligently developing a standardized clinical footprint designed for scalability across the nation and internationally. Each clinic is expected to offer a range of services, including wound care, IV therapies, neuropathy treatment, and complementary protocols. With up to 20 IV stations and five wound care treatment rooms per clinic, Thrive envisions generating $5–6 million in total revenues per location, aiming for an impressive 35% EBITDA within each clinic.
Guy Zajonc, CEO and Chairman of Thrive Precision Health, is a prime example of the company's leadership, which places a strong emphasis on precision health and personalized medicine. The CEO of True Diabetes, Dr. Jason Mulder, draws attention to the urgent need in Arizona alone, where millions of people suffer from diabetes and there is a severe shortage of treatment resources.
In the context of a burgeoning diabetes care market, Thrive Precision Health, Inc. (OTC: CNER) emerges as a compelling player with a vision to transform healthcare delivery. Their strategic acquisitions, commitment to precision health, and innovative approach position them as an intriguing opportunity within a sector poised for significant growth. As the demand for personalized diabetes care rises, CNER stands out as a potential cornerstone in this evolving narrative.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, or assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. Capital Gains Report (CGR) is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR has been retained by ACN LLC to produce and distribute this content related to CGER. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website capitalgainsreport.com All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR is not a fiduciary by virtue of any persons use of or access to this content.
Contact Details
Capital Gains Report
Mark McKelvie
+1 585-301-7700
markrmckelvie@gmail.com
Company Website
http://CapitalGainsReport.com
View source version on newsdirect.com: https://newsdirect.com/news/thrive-precision-health-inc-otc-cner-taking-steps-to-serve-diabetic-health-sector-929683000
$CNER China New Energy Group Co (OTCMKTS: CNER) is a reverse merger company that is executing on its rollup strategy of opening diabetes clinics in strategic locations resulting in quick sustainable cash flow. Follow the company on Twitter https://twitter.com/PrecisionT67828
CNER 🚀 Thrive Precision Health is all about the future! We're committed to advancing healthcare with groundbreaking technology. Our vision is clear, and our goals are ambitious. Stay updated as we make strides in the world of diabetes care! #FutureOfHealth #DiabetesManagement
🚀 Thrive Precision Health is all about the future! We're committed to advancing healthcare with groundbreaking technology. Our vision is clear, and our goals are ambitious. Stay updated as we make strides in the world of diabetes care! #FutureOfHealth #DiabetesManagement
— Thrive Precision Health (@PrecisionT67828) November 2, 2023
Hey, good morning!
Have a good evening, solid trading day today. $CNER
$CNER green here .031's thin, volume picking up!
"$CNER📉 Unlock the potential of diabetes clinics! Thrive Precision Health's strategic plan aims for multiple expansion and enhanced technology integration." 🌐💡#Innovation #HealthcareTech
https://twitter.com/PrecisionT67828
Exactly! Many positions taken today. $CNER
CNER aka Thrive is a real operating business with a bulletproof business plan run by a number of experienced health care professionals. They target patients in the second largest ongoing pandemic called diabetes. They have a scalable plan with realistic goals. The management team has decades of experience and knows what they are doing. They are leveraging the value of the public markets along with technology to create a clinic with a greater multiple than what they purchased by instituting common sense improvements that drop to the bottom line. The share structure might look scary but the shares have almost no chance of making it into the float due to the affiliate status, the financier lockup, or the 100 million in zombie stock. The tight float will ultimately create volatility to the up or downside however the downside risk is muted thanks to a long term investor and a scarcity of shares. The company is seeing an uptick in volume, has some good press flow, and could be a good long term hold for investors that want a slice of the 2nd largest pandemic market in the world.
|
Followers
|
6
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
121
|
|
Created
|
11/17/07
|
Type
|
Free
|
| Moderators | |||
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here.
